Meek inherits CCO job at Endocyte
This article was originally published in Scrip
Endocyte, a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalised therapy, has appointed David Meek chief commercial officer. Mr Meek joins Endocyte having served seven years at Novartis, where he was most recently head of northern and central Europe oncology. He previously served in senior positions at Johnson & Johnson for 15 years.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.